Related Experiment Video

Updated: Dec 13, 2025

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.8K

Prognostic value of serum amyloid A in patients with COVID-19

Li Cheng1, Jian-Zhong Yang2, Wen-Hui Bai3

  • 1Intensive Care Unit, Renmin Hospital of Wuhan University, Eastern Campus, Wuhan, China.

Infection
|August 1, 2020
PubMed

Insights

Serum amyloid A (SAA) shows significant prognostic value in predicting outcomes for patients with COVID-19. Elevated SAA levels after treatment indicate a poorer prognosis, making it a sensitive biomarker for COVID-19 patient outcomes.

Area of Science:

  • Clinical Medicine
  • Infectious Diseases
  • Biomarkers

Background:

  • The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality worldwide.
  • Identifying reliable prognostic markers is crucial for managing COVID-19 patients and optimizing treatment strategies.

Purpose of the Study:

  • To evaluate the prognostic significance of serum amyloid A (SAA) levels in patients diagnosed with COVID-19.
  • To determine if SAA can serve as an early indicator of patient outcomes.

Main Methods:

  • A cohort of 89 COVID-19 patients was analyzed, divided into survival and non-survival groups based on 28-day follow-up.
  • Serum amyloid A (SAA) levels were measured on admission and at 3, 5, and 7 days post-treatment.
  • Receiver Operating Characteristic (ROC) curve analysis was employed to assess the prognostic accuracy of SAA.

Main Results:

  • While initial SAA levels before treatment did not significantly differ between groups, levels at 3, 5, and 7 days post-treatment were significantly higher in the non-survival group (P < 0.001).
  • ROC analysis demonstrated high sensitivity for SAA in predicting prognosis at various time points (e.g., 97.2% at 3 days, 96.1% at 7 days).
  • SAA exhibited superior sensitivity compared to other inflammatory markers like C-reactive protein and leukocyte counts at day 7.

Conclusions:

  • Serum amyloid A (SAA) is a valuable and sensitive biomarker for predicting prognosis in COVID-19 patients.
  • Serial monitoring of SAA levels can aid in assessing disease severity and patient outcomes.
Abstract

Keywords:
COVID-19PrognosisSerum amyloid A

More Related Videos

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay05:45

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

24.0K
Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

5.8K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.4K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
330